Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Femara shows reduced risk of death versus tamoxifen after breast cancer surgery

Femara showed reduced risk of death by 13% (P=0.08) versus tamoxifen, despite inclusion of patients who had switched over from tamoxifen to Femara during the study period, following the study's unblinding.

14 Dec 2008

Early-stage breast cancer patients with HER2 positive tumors at increased risk of recurrence

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

14 Dec 2008

Aromatase inhibitors most effective in preventing breast cancer from coming back

Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back.

12 Dec 2008

Surge in older cancer survivors expected as baby boomers age

The United States could be faced with a national health care crisis in the coming decades as the country's baby boomer population ages and a growing number of older adults find themselves diagnosed with and living longer with cancer.

10 Dec 2008

$Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma$

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

10 Dec 2008

Hormone therapy for prostate cancer does not appear to increase cardiac deaths

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers.

10 Dec 2008

UK's first prostate cancer patient treated using RapidArc radiotherapy

65-year-old grandfather of six, Graham McCormack has become the first cancer patient in the UK to be treated using RapidArc radiotherapy technology from Varian Medical Systems.

10 Dec 2008

Experimental drug successfully blocks mutation in bone marrow cancers

Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.

10 Dec 2008

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.

10 Dec 2008

Dacogen data presented on trial in seniors with acute myeloid leukemia

Eisai Corporation of North America has announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia.

10 Dec 2008

New systems to standardize studies of neuroblastomas

An international coalition of pediatric cancer physicians and researchers has developed new systems to standardize studies of neuroblastomas across the world.

10 Dec 2008

When less is more: Brief inhibition of cancer target is effective and less toxic

New research shows that the delicate balance between maximum clinical impact and toxicity may not be quite as fragile as scientists had previously believed.

8 Dec 2008

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.

8 Dec 2008

Levels of insulin-related proteins indicate risk of death in some colorectal cancer patients

A pair of proteins may help explain why people with surgically removed colorectal cancer and who are overweight, physically inactive, and follow a Western-pattern diet may have an increased risk of dying of the disease or other causes, Dana-Farber Cancer Institute scientists report in a new study.

8 Dec 2008

Mammography screening in women over 80

A lack of clear-cut, scientific evidence illustrating the benefits of mammography screening in women over 80 has created a trail of controversy leading to a disturbing conclusion about cancer care in America.

8 Dec 2008

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Startling findings from a new CML (chronic myelogenous leukemia) patient survey were presented at a satellite meeting of the American Society of Hematology annual meeting, in San Francisco.

8 Dec 2008

Cambridge Labs announces Spanish approval of Tetrabenazine

Cambridge Laboratories Limited has announced that its flagship product Tetrabenazine, (known as NITOMAN in Germany and other key European territories and XENAZINE in the UK, U.S. and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

8 Dec 2008

Gene therapy used to fight AIDS

The apparent success of a case in which German doctors cured a man of AIDS using a bone marrow transplant comes as no surprise to Gerhard Bauer, a UC Davis stem cell researcher.

8 Dec 2008

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.

8 Dec 2008

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia (CLL) has shown promising results in two phase I and II clinical trials, according to researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

8 Dec 2008

Oncology News and Research

Further Reading

Femara shows reduced risk of death versus tamoxifen after breast cancer surgery

Early-stage breast cancer patients with HER2 positive tumors at increased risk of recurrence

Aromatase inhibitors most effective in preventing breast cancer from coming back

Surge in older cancer survivors expected as baby boomers age

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Hormone therapy for prostate cancer does not appear to increase cardiac deaths

UK's first prostate cancer patient treated using RapidArc radiotherapy

Experimental drug successfully blocks mutation in bone marrow cancers

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Dacogen data presented on trial in seniors with acute myeloid leukemia

New systems to standardize studies of neuroblastomas

When less is more: Brief inhibition of cancer target is effective and less toxic

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Levels of insulin-related proteins indicate risk of death in some colorectal cancer patients

Mammography screening in women over 80

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Cambridge Labs announces Spanish approval of Tetrabenazine

Gene therapy used to fight AIDS

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

Event guide: The 9th DDR Inhibitors Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News